Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Kim D.; Mehra R.; Tan D. S. W.; Felip E.; Chow L. Q. M.; Camidge D. R.; Vansteenkiste J.; Sharma S.; De Pas T.; Riely G. J.; Solomon B. J.; Wolf J.; Thomas M.; Schuler M.; Liu G.; Santoro A.; Geraldes M.; Boral A. L.; Yovine A.; Shaw A. T.

首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

【24h】

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

机译：Ceritinib在晚期间变性再生性淋巴瘤激酶（ALK）重排（ALK plus）非小细胞肺癌（NSCLC）患者中的疗效和安全性：ASCEND-1的更新

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Radiation Oncology, Biology, Physics》 |2014年第5suppla期|共2页
作者
Kim D.; Mehra R.; Tan D. S. W.; Felip E.; Chow L. Q. M.; Camidge D. R.; Vansteenkiste J.; Sharma S.; De Pas T.; Riely G. J.; Solomon B. J.; Wolf J.; Thomas M.; Schuler M.; Liu G.; Santoro A.; Geraldes M.; Boral A. L.; Yovine A.; Shaw A. T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 [J] . Kim D., Mehra R., Tan D. S. W., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Ceritinib在晚期间变性再生性淋巴瘤激酶（ALK）重排（ALK plus）非小细胞肺癌（NSCLC）患者中的疗效和安全性：ASCEND-1的更新
2. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial [J] . Kim Dong-Wan, Mehra Ranee, Tan Daniel S. W., The lancet oncology . 2016,第4期

机译：ceritinib在ALK重排非小细胞肺癌（ASCEND-1）患者中的活性和安全性：多中心，开放标签，1期试验的最新结果
3. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong [J] . Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Cost Effectiveness Resource Allocation . 2020,第1期

机译：Ceritinib与克里齐替尼在预先治疗的促进性淋巴瘤激酶（ALK） - 阳性非小细胞肺癌（NSCLC）中的成本效果分析
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1 multicentre open-label ASCEND-1 trial [O] . Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, -1

机译：ceritinib对未接受过ALK抑制剂治疗和先前接受过ALK抑制剂治疗的ALK重排非小细胞肺癌（NSCLC）患者的颅内和全身反应：第一阶段多中心开放标签ASCEND-1的最新结果试用
7. 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials [O] . E. Felip, L. Crinò, D.-W. Kim, 2016

机译：141PD：Ceritinib在患者（PTS）中的全身和颅内疗效，用克里齐替尼（CRZ）预处理，ALK重新排列（ALK +）非小细胞肺癌（NSCLC）和基线脑转移（BM）：升降升降机Ascend-2试验

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

著录项

相似文献

相关主题

期刊订阅